1.
Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
Brown David M, Michels Mark, Kaiser Peter K, Heier Jeffrey S, Sy Judy P, Ianchulev Tsontcho
OphthalmologyJan 20091129 citationsRandomized Controlled Trial
In neovascular AMD, ranibizumab significantly outperformed verteporfin PDT over two years, improving visual acuity and anatomical outcomes, establishing it as a superior treatment.